Pharma AI Hiring Trends 2026: Top Drugmakers Census

Pharmaceutical companies enter the second half of 2026 amid a genuinely unusual labor market: broad headcount is contracting at several large drugmakers while public disclosures show visible AI-related investment and selected hiring signals. BioSpace's 2026 U.S. Life Sciences Employment Outlook found that 64% of surveyed biopharma organizations were actively recruiting in late 2025, up from 59% a year earlier, and 41% expect their open-role count to grow in 2026 (^[1]), even after the industry recorded roughly 42,700 layoffs in 2025, a 47% jump over 2024 (^[2]). Across the wider United States economy, the share of firms with at least one AI-related job posting on Indeed nearly tripled from 2% in 2018 to 5.7% by November 2025, though almost 90% of that posting volume is concentrated among just 1% of hiring firms (^[3]) (^[4]). This economy-wide pattern does not by itself establish how AI hiring is distributed within pharma.

Public disclosures provide selected examples of large drugmakers investing in AI organizations, infrastructure, partnerships, and, in some cases, named roles; they do not establish a census of a defined top-20 group or a common level of current hiring. Novartis is hiring an Executive Director of Applied AI in Basel as part of what it calls an "AI-first" transformation (^[5]); Roche's Genentech unit runs a Computational Sciences Center of Excellence launched in 2025 atop more than 3,500 GPUs, the largest publicly disclosed compute footprint of any pharmaceutical company (^[6]); Eli Lilly and Nvidia are jointly investing up to $1 billion over five years in a co-innovation AI lab (^[7]); and Merck signed an agentic-AI partnership with Google Cloud valued at up to $1 billion (^[8]). Compensation data from Levels.fyi and Built In shows Data Scientist total pay at large pharma employers running from a $165,000 median at Eli Lilly to a $222,000 median at Gilead Sciences (^[9]) (^[10]), while director- and VP-level AI leadership postings at Pfizer and Merck reach into the $270,000 to $427,000 range (^[11]).

These selected AI-related signals are unfolding against a record dealmaking backdrop: EY tracked $240 billion in global life sciences mergers and acquisitions (M&A) in 2025, an 81% increase over 2024, backed by a record $2.1 trillion in acquisition "firepower" heading into 2026 (^[12]), while Deloitte independently confirmed 193 transactions worth $220 billion through November 2025 (^[13]). Recruiters describe a "barbell" market in which large-scale restructuring, including Novo Nordisk's cut of approximately 9,000 roles (11.5% of its workforce) (^[14]) and Bayer's reduction of about 13,500 positions since 2024 (^[15]), coexists with searches for AI-aware specialists that frequently run six to nine months (^[16]). The remainder of this report details selected company signals, job titles and compensation benchmarks, the regulatory backdrop set by the joint FDA/European Medicines Agency (EMA) AI principles issued in January 2026, and what the data implies for organizations competing for this talent through 2026 and beyond.

The pharmaceutical industry's relationship with artificial intelligence shifted in 2025 and 2026 from experimentation to organizational commitment. What began as isolated data science teams embedded in research and development (R&D) has, at many of the world's largest drugmakers, become a distinct functional layer with its own executives, budgets, and hiring pipelines. This report examines pharma AI hiring trends 2026 through selected public signals: which companies have disclosed formal AI organizations, investments, partnerships, or roles; how the broader life-sciences labor market is behaving; and how mergers and acquisitions (M&A) and workforce restructuring provide employment context. It does not measure comparable company-level AI hiring, compensation, or talent flows.

The context matters because pharma's AI hiring is not occurring in isolation from the industry's broader employment picture. BioSpace's 2026 outlook survey of 136 talent-acquisition and workforce-planning professionals found recruitment activity varies enormously by company size, with 100% of respondents at firms of 500 to 999 employees actively recruiting compared with just 37% at firms under 50 employees (^[17]). At the same time, the industry absorbed roughly 42,700 layoffs in 2025 (^[2]), meaning AI hiring gains are concentrated rather than uniformly distributed.

Regulators have also begun to formalize expectations around AI use in drug development. In January 2026, the FDA and EMA jointly identified ten guiding principles for AI use across the medicines lifecycle, covering everything from early research through manufacturing and post-market safety monitoring (^[18]), with guidance intended to apply broadly to evidence generation and monitoring at every phase of a medicine's development (^[19]).

Regulatory formalization and publicly announced AI investment provide context for the organizational developments discussed in the sections that follow.

Quantifying "AI hiring" in pharma requires triangulating between general labor-market data and life sciences specific sources, since few companies publish a clean count of AI-titled roles. Three data points frame the scope. First, general AI hiring intensity: Indeed's Hiring Lab reported that the share of United States employers posting at least one AI-related job listing rose from about 2% in 2018 to 5.7% by November 2025 (^[3]), but that growth is highly concentrated: almost 90% of AI-related postings originated from just 1% of hiring firms, and among adopters more than 40% of postings by late 2025 mentioned AI-related keywords (^[20]). The economy-wide analysis does not identify pharmaceutical companies separately and therefore cannot establish where pharma employers fall within that distribution.

Second, biopharma's overall hiring outlook. BioSpace's 2026 U.S. Life Sciences Employment Outlook found 64% of surveyed organizations were actively recruiting at the end of 2025, up from 59% in the 2024 survey, and 41% predicted their number of open roles would increase in 2026, nearly matching the 42% who expected growth heading into 2025 (^[21]). By function, clinical roles led expected 2026 hiring at 48% of respondents, followed by manufacturing and production at 38% and regulatory affairs at 37% (^[22]), while 29% of workforce planners specifically expect to hire for broader technology roles, the category that captures most data science and AI positions (^[23]).

Third, the value case driving that hiring. McKinsey's life sciences practice estimated in 2023 that generative AI (GenAI) could unlock between $60 billion and $110 billion a year in economic value for pharmaceutical and medical products companies (^[24]), yet a subsequent McKinsey survey of more than 100 pharma and medtech leaders found only 32% had taken concrete steps to scale the technology and just 5% said they had realized GenAI as a competitive differentiator generating consistent financial value (^[25]) (^[26]). A separate Deloitte-sourced figure reported by trade press put the share of executives who had already seen return on their AI investments at just 9% as of early 2026 (^[27]). The gap between value potential and realized value highlights the implementation challenges companies face, but these survey findings do not establish why individual companies make hiring decisions.

The following analysis summarizes publicly disclosed AI organization-building, investments, partnerships, and roles among the eleven named drugmakers in Table 1. It is not a ranking of a defined top-20 revenue universe and does not establish comparable current hiring intensity across the companies. Novartis brought in Sander Timmer as Global Head of Data Science and AI for Global Drug Development in Basel (^[28]) and is separately recruiting an Executive Director of Applied AI as part of a long-term push to become an "AI-first organization" with sponsorship at the highest levels of the company (^[5]). Roche, through its Genentech unit, launched a Computational Sciences Center of Excellence (CSCoE) in 2025 that pools computational scientists from both organizations, backed by a combined on-premise and cloud compute footprint exceeding 3,500 graphics processing units (GPUs), which Genentech describes as the largest announced GPU footprint at any pharmaceutical company (^[29]) (^[6]).

Pfizer has built out a multi-tier AI executive structure under Jeremy Forman, who was promoted to Chief AI, Data & Analytics Officer, with two new vice-president-level roles, Head of AI Center of Excellence and Chief AI Architect, reporting to him (^[30]). Pfizer is simultaneously hiring a Head of AI Clinical Excellence to lead AI application across the clinical development lifecycle (^[31]). Eli Lilly and Nvidia announced a co-innovation AI lab that will co-locate Lilly's biology, science, and medicine experts with Nvidia's AI model builders and engineers in the San Francisco Bay Area, backed by up to $1 billion in combined talent, infrastructure, and compute investment over five years (^[32]).

AstraZeneca has created a dedicated Enterprise AI Unit as a global center of excellence spanning R&D, commercial, operations, and corporate functions, led by Chief Digital, Data and AI Officer Anne-Claire Gerbaldi (^[33]), paired with a company-wide "100% workforce AI proficiency commitment" that frames AI competence as core to every role, not just specialist teams (^[34]). The company is separately recruiting an Executive Director, Global Head of Medical AI/Digital Strategy & Enablement to extend AI and data tools across more than 3,000 medical colleagues (^[35]). Merck signed a multi-year agentic AI partnership with Google Cloud valued at up to $1 billion, deploying an agentic platform (Gemini Enterprise) across research, manufacturing, commercial, and corporate functions for its roughly 75,000 employees (^[8]) and separately entered an AI-enabled drug discovery and precision medicine research agreement with Mayo Clinic (^[36]).

Several other top-20 drugmakers show similar patterns. GSK signed a deal worth up to $110 million with AI biotech Relation to build large-scale human cellular perturbation datasets for its AI models (^[37]). Johnson & Johnson entered a cross-modality, multi-target AI drug discovery research collaboration with Alphabet-backed Isomorphic Labs spanning small molecules, antibodies, peptides, and molecular glues (^[38]) and is separately hiring a Vice President, AI Next Frontiers Strategy and Execution within its Data Analytics & Computational Sciences function (^[39]). Novo Nordisk built a governed reasoning agent on Microsoft Azure that Microsoft says reduced time to insight for clinical data analysis from weeks to minutes while increasing analytical throughput (^[40]), and the company maintains a Chief AI Officer and Group Vice President of Enterprise AI position. Sanofi describes itself as an "R&D-driven, AI-powered biopharma company" organized around three AI pillars, with 20,000 employees using its internal "plai" AI application daily (^[41]), and Boehringer Ingelheim opened a fourth AI/machine learning (ML) center in London in April 2026, following existing sites in Austria, Germany, and the United States (^[42]), recruiting AI scientists, ML engineers, research engineers, data engineers, MLOps (machine learning operations) engineers, and AI infrastructure engineers into the new hub (^[43]).

Table 1 summarizes publicly disclosed AI-related organizational activity among eleven named large drugmakers as of August 2026. It is neither a ranking nor a comprehensive census of a defined top-20 or top-25 revenue universe, and the listed signals may describe partnerships, infrastructure, or planned roles rather than a documented current opening.

The examples show different forms of AI-related activity, including named leadership roles, centers of excellence, partnerships, infrastructure, and individual postings. Because public disclosures do not consistently provide AI headcount, opening counts, or comparable organizational structures, they cannot establish a uniform hiring pattern or rank the companies by hiring intensity.

Pharma AI job titles cluster into a few recurring families: enterprise AI leadership (Chief AI Officer, Chief Digital and AI Officer), functional AI leadership (Head of AI Clinical Excellence, Head of AI Center of Excellence, Chief AI Architect), and technical practitioner roles (Data Scientist, Machine Learning Engineer, Computational Biologist, AI Scientist, MLOps Engineer). Compensation varies substantially by seniority, company, and whether the role sits in a general data science track or a more specialized AI leadership track.

At the practitioner level, Levels.fyi crowdsourced data puts the median total compensation for a Data Scientist at Eli Lilly and Company in the United States at $165,000 per year (^[9]), while the equivalent median at Gilead Sciences is $222,000 (^[10]). A live Merck posting for Associate Director, Functional Genomics, Data Science in Cambridge, Massachusetts lists a base salary range of $176,200 to $277,300 (^[44]). Job-board listings show similar bands elsewhere: an AbbVie Principal Research Data Scientist role focused on artificial intelligence (AI)-ready data solutions, large language models (LLMs), and generative AI applications for pharmaceutical R&D lists $125,000 to $237,000 annually (^[45]), and a Genentech Senior Data Scientist role focused on AI-assisted clinical development lists $143,000 to $265,000 (^[46]). Built In's aggregate 2026 data for United States Data Scientists across all industries shows an average base salary of $128,067 and average total compensation of $145,852 (^[47]), suggesting pharma-specific postings, particularly those explicitly tied to AI or generative AI work, tend to sit at or above the broader market average.

At the leadership tier, listed base-pay ranges climb sharply. Pfizer's Head of AI Clinical Excellence posting lists an annual base salary range of $176,600 to $294,300 (^[31]), and Built In’s reproduction of Pfizer’s VP, Head of AI Center of Excellence posting lists an annual base salary range of $274,000 to $426,800. That VP posting separately describes eligibility for a target bonus and share-based long-term incentives; it does not state total compensation (^[11]).

Skills demand is shifting alongside titles. Panda International, drawing on data it attributes to the Association of the British Pharmaceutical Industry (ABPI), reports that 43% of pharma companies struggle to find candidates with the digital literacy skills now required across the workforce (^[48]), and separately notes that AI-aware roles, alongside senior regulatory affairs and cell and gene therapy chemistry, manufacturing and controls (CMC) leadership, frequently take six to nine months to fill (^[16]). Pharma is competing directly with AI-native biotechs, including Isomorphic Labs, Recursion, Insilico, and Xaira, plus big-pharma AI labs, for the same computational biology and machine learning scientist pool (^[49]), and recruiters note that AI-native firms typically run interview processes in two to three weeks, while a traditional pharma process taking six to eight weeks routinely loses candidates in the gap even when the eventual offer is competitive (^[50]).

Table 2 below consolidates the compensation data points gathered for pharma AI and data science roles as of August 2026, drawn from company career pages, Levels.fyi, and Built In.

The spread in this table, from the $125,000 low end of the listed posting ranges to $427,000 for VP-level AI leadership, illustrates why recruiters describe pharma AI hiring as bifurcated: broad technical roles compete on pay with the general technology sector, while a much smaller set of AI leadership positions command premiums reflecting both scarcity and the strategic weight companies are now placing on those roles.

Pharma AI hiring in 2026 cannot be separated from an unusually active M&A market. EY's global life sciences M&A Firepower report found the industry closed $240 billion in M&A investment in 2025, an 81% increase over the $130 billion recorded in 2024, with the average deal size rising 107% (^[51]), and it projects a record $2.1 trillion of dealmaking capacity, or "firepower," heading into 2026 (^[12]). Deloitte's independent tally corroborates the scale: 193 life sciences transactions totaling $220 billion by the end of November 2025, surpassing 2024's total deal value, with average deal size rising by $450 million year over year, a 70% increase (^[13]) (^[52]). PwC's midyear United States deals outlook shows pharma and life sciences deal value surpassed $65 billion in the first quarter of 2026 alone, the strongest quarter since 2020 (^[53]), driven in part by an estimated $300 billion-plus of branded pharma revenue facing loss of exclusivity this decade (^[54]). Named 2026 transactions illustrate the pattern, including Merck's agreement to acquire Terns Pharma for $6.7 billion (^[55]).

This dealmaking is occurring alongside significant workforce restructuring at some of the same companies expanding their AI functions. Novo Nordisk announced on September 10, 2025 that it intends to reduce its global workforce by approximately 9,000 positions (^[56]), roughly 11.5% of its 78,400-person global workforce (^[14]), as part of a plan targeting 8 billion Danish kroner in annualized savings. Bayer has let go of about 13,500 employees, including around 5,000 managers, since introducing its Dynamic Shared Ownership operating model in early 2024, with reductions continuing through the third quarter of 2025 (^[15]). Despite this, EY's Americas life sciences leader has projected the industry's overall 2026 layoff rate will likely stay below 5% (^[57]), meaning general restructuring and targeted AI hiring are, for now, distinct and largely non-overlapping trends rather than a single coherent workforce strategy. Sanofi's announcement illustrates a planned AI investment: it committed $294 million to expand its Toronto AI Centre of Excellence and said the investment will create 50 new AI/ML roles by 2028, building on more than 150 roles created since the center was established in 2022 (^[58]).

The quantitative evidence gathered for this report identifies several patterns across sources with different methods and scopes. First, AI-related hiring adoption is rising but concentrated. Indeed's Hiring Lab found that the share of United States firms with at least one AI-related job posting grew from 2% in 2018 to 5.7% in November 2025 (^[3]), and within that growth almost 90% of postings came from just 1% of employers (^[4]), a distribution consistent with the article's focus on selected large drugmakers.

Second, several publicly disclosed AI initiatives in the examples below involve nine- or ten-figure commitments. Individual company-level AI investments verified in this research include Lilly and Nvidia's up to $1 billion, five-year co-innovation lab (^[7]), Merck and Google Cloud's up to $1 billion agentic AI partnership (^[8]), GSK's up to $110 million data partnership with Relation (^[37]), and Sanofi's $294 million Toronto AI Centre of Excellence expansion (^[58]). These figures sit inside a macro M&A environment where EY recorded $240 billion in total 2025 life sciences dealmaking, an 81% year-over-year increase (^[51]).

Third, the value-realization gap remains wide relative to the investment scale. McKinsey's 2023 estimate placed GenAI's annual value opportunity for pharma and medical products at $60 billion to $110 billion (^[24]), yet its later survey of industry leaders found only 5% had realized that value as a measurable competitive differentiator (^[25]), and a Deloitte-derived figure cited in trade press put executive-reported AI return on investment (ROI) at just 9% as of early 2026 (^[27]). The gap between investment and realized ROI underscores the difficulty of translating AI investment into measurable value. The cited evidence does not show whether individual organizations respond by expanding specialist hiring, changing operating models, or taking other actions.

Table 3 below consolidates the report's headline dealmaking and workforce figures for quick reference.

Taken together, these figures show that publicly disclosed AI investment and organizational activity are concentrated among several large drugmakers, while smaller and mid-sized organizations report skills gaps and longer time-to-fill windows. They do not demonstrate a relationship between balance-sheet capacity and a company’s hiring pipeline, or establish why an individual company makes hiring decisions.

Three neutral, publicly documented deployments illustrate AI-related operational and infrastructure initiatives at large drugmakers.

Eli Lilly and Nvidia's Co-Innovation AI Lab

Announced in January 2026, the Lilly-Nvidia lab is structured explicitly around talent co-location: Lilly's biology, science, and medicine domain experts will work alongside Nvidia's AI model builders and engineers in the same Bay Area facility (^[32]), backed by up to $1 billion in combined investment in talent, infrastructure, and compute over five years (^[7]). The structure represents one of the clearest publicly disclosed examples of a pharma company directly embedding external AI talent inside its own drug discovery workflow, rather than purchasing AI tools as a service.

Merck and Google Cloud's Agentic AI Rollout

Merck's up to $1 billion, multi-year agreement with Google Cloud is notable for its enterprise-wide scope: the agentic AI platform (Gemini Enterprise) is being deployed across R&D, manufacturing, commercial, and corporate functions for the company's approximately 75,000 employees (^[8]). The announcement documents deployment scope and Google Cloud engineering support, but does not quantify Merck hiring needs or current openings.

Sanofi's Toronto AI Centre of Excellence

Sanofi's Toronto hub demonstrates sustained, multi-year AI hiring rather than a single announcement. Established in 2022, the center had created more than 150 roles by 2026, at which point Sanofi committed a further $294 million and 50 additional AI/ML jobs to the site (^[58]). The pattern (an initial center of excellence followed by a staged reinvestment years later) offers a template other large drugmakers appear to be following with their own regional AI hubs, including Boehringer Ingelheim's newest center in London (^[42]).

The evidence gathered in this report documents AI-related activity at selected large drugmakers through the remainder of 2026. It does not establish that nearly every profiled company created or filled a comparable AI leadership role within the past 18 months, or that such roles will proliferate at a predictable rate. At the same time, the "barbell" hiring pattern recruiters describe, aggressive specialist competition for AI-aware talent alongside broad workforce restructuring, is unlikely to fully resolve in the near term, since EY's below-5% 2026 layoff projection (^[57]) still implies continued restructuring even as AI-specific hiring accelerates.

The joint FDA/EMA AI guiding principles issued in January 2026 provide broad guidance for AI use in evidence generation and monitoring across the medicines lifecycle. EMA says the principles are relevant to medicine developers and marketing-authorisation applicants and holders, and will underpin future guidance; they do not prescribe hiring criteria or establish a candidate-validation requirement (^[18]).

Organizations without the scale to fund large internal AI labs may weigh internal capability-building, partnerships, and other operating-model choices against their specific use cases, resources, and regulatory obligations. Indeed Hiring Lab's US-wide analysis shows that AI-related hiring remains concentrated among a small share of very large employers; it does not establish which implementation approach is best for a particular life sciences organization (^[4]).

What kinds of AI jobs are available in the pharmaceutical industry in 2026? Roles range from enterprise leadership titles such as Chief AI Officer and Chief Digital and AI Officer, to functional leadership roles like Head of AI Clinical Excellence and Head of AI Center of Excellence, down to practitioner roles including Data Scientist, Machine Learning Engineer, Computational Biologist, and MLOps Engineer. Boehringer Ingelheim's disclosed talent-pool roles cover several technical practitioner specialties, from AI scientists to AI infrastructure engineers, at its newly opened AI center (^[43]).

What data science jobs are available at pharma companies right now? Data science roles can span general analytics and specialized tracks such as functional genomics, oncology data science, and AI-assisted clinical development. A third-party listing reproduces a $176,200 to $277,300 base-pay range for Merck's Associate Director, Functional Genomics, Data Science role; readers should confirm availability and compensation on Merck's careers site (^[44]).

Which selected large drugmakers show public AI-related activity in 2026? Table 1 identifies selected large drugmakers with public AI-related organizational activity, investments, partnerships, or roles as of mid-2026. Those disclosures are not comparable measures of current hiring, so they cannot identify which companies are hiring most aggressively. Roche's Genentech unit has disclosed more than 3,500 GPUs supporting its Computational Sciences Center of Excellence (^[6]).

What job titles and salaries are typical for pharma AI roles? Titles range from Data Scientist (median total compensation $165,000 to $222,000 at companies such as Lilly and Gilead) (^[10]) up to VP-level AI Center of Excellence leadership roles reported at $274,000 to $427,000 (^[11]).

What AI skills are in highest demand across the pharmaceutical industry? Recruiters point to computational biology and machine learning expertise applied to drug discovery, and generative AI and large language model deployment in regulated settings, as the most sought skills; only 32% of surveyed pharma and medtech leaders say they have taken concrete steps to scale generative AI internally, underscoring how much of that skill set organizations are still building rather than already possessing (^[26]).

How would you describe the biopharma AI talent market in 2026 overall? It is a "barbell" market: broad hiring caution and, at some companies, large restructuring, coexist with acute, narrow demand for AI-aware and computational talent. BioSpace found 64% of biopharma organizations were actively recruiting in late 2025 (^[1]), even as the industry recorded roughly 42,700 layoffs the same year (^[2]).

How does Data Scientist salary vary by pharma company? Verified figures in this report range from a $165,000 median at Eli Lilly (^[9]) to a $222,000 median at Gilead Sciences (^[10]), with specific posted ranges at Merck, AbbVie, and Genentech overlapping or extending beyond those figures, as detailed in Table 2.

Where can readers find a broader life sciences AI hiring report? BioSpace publishes an annual U.S. Life Sciences Employment Outlook survey of biopharma hiring intentions; its 2026 edition drew on 136 talent-acquisition and workforce-planning respondents (^[21]). Indeed's Hiring Lab also publishes ongoing United States labor-market data tracking AI-related job postings by industry and firm size (^[3]).

Pharma companies are making visible AI-related investments in 2026, particularly among large organizations. The eleven companies profiled here have publicly disclosed different combinations of leadership roles, partnerships, infrastructure, and hiring hubs; these disclosures do not establish that each company has the same organizational maturity or current hiring intensity. Published compensation figures also span a wide range, but they combine crowdsourced estimates and individual third-party job listings rather than a validated market survey. The available evidence supports a narrower conclusion: AI-related activity is visible at large drugmakers while broader life-sciences employment remains affected by dealmaking and restructuring. Public disclosures alone cannot determine the optimal hiring or implementation strategy for a particular organization.